These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37797288)

  • 21. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study.
    Emsley R; Nuamah I; Gopal S; Hough D; Fleischhacker WW
    J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
    Buckley PF; Schooler NR; Goff DC; Hsiao J; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz AJ; Miller del D; Severe JB; Wilson DR; Ames D; Bustillo J; Mintz J; Kane JM;
    Schizophr Bull; 2015 Mar; 41(2):449-59. PubMed ID: 24870446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
    Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
    Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Tiihonen J; Tanskanen A; Taipale H
    Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.
    Moncrieff J; Crellin N; Stansfeld J; Cooper R; Marston L; Freemantle N; Lewis G; Hunter R; Johnson S; Barnes T; Morant N; Pinfold V; Smith R; Kent L; Darton K; Long M; Horowitz M; Horne R; Vickerstaff V; Jha M; Priebe S
    Lancet Psychiatry; 2023 Nov; 10(11):848-859. PubMed ID: 37778356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.
    Wunderink L; Nienhuis FJ; Sytema S; Slooff CJ; Knegtering R; Wiersma D
    J Clin Psychiatry; 2007 May; 68(5):654-61. PubMed ID: 17503973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
    Kishi T; Citrome L; Sakuma K; Iwata N
    Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial.
    Saito Y; Sakurai H; Kane JM; Schooler NR; Suzuki T; Mimura M; Uchida H
    Schizophr Res; 2020 Jan; 215():173-180. PubMed ID: 31672387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
    Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
    Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
    Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
    J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
    Kane JM; Harary E; Eshet R; Tohami O; Weiser M; Leucht S; Merenlender-Wagner A; Sharon N; Davis GL; Suett M; Franzenburg KR; Correll CU
    Lancet Psychiatry; 2023 Dec; 10(12):934-943. PubMed ID: 37924833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.